Interactions between DOACs and cardiovascular drugs cause haemorrhage | Synapse
May 21, 2026
Interactions between DOACs and cardiovascular drugs cause haemorrhage
Key Points
This research aims to investigate the interactions between direct oral anticoagulants (DOACs) and cardiovascular medications leading to haemorrhage.
Analyzed data from various clinical trials involving DOACs and cardiovascular drugs.
Conducted quantitative assessments to identify the rate of haemorrhage associated with these drug combinations.
Evaluated patient outcomes in relation to the type of drug interactions.
Identified a significantly increased haemorrhage rate in patients using both DOACs and specific cardiovascular drugs (RR 2.3, 95% CI 1.5-3.5, p=0.002).
Observed that patients on DOACs and beta-blockers had a higher incidence of major bleeding events (OR 1.8, 95% CI 1.1-2.8, p=0.03).
Noted variations in bleeding risk based on patient demographics and specific drug pairs.